Ophthalmology Doctors in Grapevine, TX Accepting Medicare

3 Ophthalmology doctors found. Showing 1 - 3

Phillips Kirk Labor, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2201 Westgate Plaza, Grapevine, TX 76051 Phone: 817-410-2030    Fax: 817-251-6261

Dr. John Tong, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1631 Lancaster Dr, Ste 200, Grapevine, TX 76051 Phone: 817-329-5433    Fax: 817-329-5532

Michael Mong, Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1600 W College St, #390, Grapevine, TX 76051 Phone: 817-481-8955

News Archive

Neovasc Reducer three-year follow-up data presented at 2010 ACC annual meeting

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.

Stanford study shows PEPFAR program saved a million lives

The President's Emergency Plan for AIDS Relief, the ambitious U.S. government program begun in 2003, has cut the death toll from HIV/AIDS through 2007 by more than 10 percent in targeted countries in Africa, though it has had no appreciable effect on prevalence of the disease in those nations, according to a study from the Stanford University School of Medicine that is the first to evaluate these outcomes.

Earlier intervention can lead to better recovery in underweight children with multiple household risk factors

Young children who are underweight experienced greater weight recovery the earlier an intervention was started, and the recovery was more significant in children with multiple household risk factors, according to a study published this week in The Journal of Pediatrics.

Bausch + Lomb's sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

Potential blood test for chronic sinusitis identified

A protein profile has been identified in the blood of chronic sinusitis sufferers that may enable physicians to objectively diagnosis and treat the disease, researchers say.

Read more Medical News

› Verified 5 days ago